

Datasheet for ABIN5668247

Recombinant anti-CD4 (Clenoliximab Biosimilar) antibody[Go to Product page](#)**2** Images

Overview

Quantity:	200 µg
Target:	CD4 (Clenoliximab Biosimilar)
Reactivity:	Chimpanzee, Human
Host:	Human
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	Un-conjugated
Application:	Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunohistochemistry (IHC), Surface Plasmon Resonance (SPR)

Product Details

Immunogen:	Domain 1 of human CD4.
Clone:	CE9-1
Isotype:	IgG4 lambda
Specificity:	The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 µg/mL.
Characteristics:	OriginalSpeciesName: Human OriginalFormat: IgG4 (primatized)
Purification:	Purified antibody.
Purity:	> 98 % as determined by SDS-PAGE
Endotoxin Level:	Endotoxin is < 1.0 EU/mg as determined by the LAL method

Target Details


Target:	CD4 (Clenoliximab Biosimilar)
Target Type:	Biosimilar
Background:	P55, T cell surface antigen T4/Leu-3.
UniProt:	P01730

Application Details

Application Notes:	The antibody binds specifically to CD4, a molecule which is part of the immunoglobulin superfamily, expressed on the surface of helper T cells. The CD4 Molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as 'primatized', as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and ?4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec.
Comment:	NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques.
Restrictions:	For Research Use only


Handling

Buffer:	PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C, -20 °C
Storage Comment:	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.



Immunohistochemistry

Image 1. Immunohistochemical staining of guinea pig skin using anti-CD4 antibody. CE9.1 (Clenoliximab) Anti-CD4 staining of formaldehyde fixed paraffin embedded guinea pig skin tissue, at 40x magnification. The human IgG4-chimeric version of CE9.1 (Clenoliximab) (ABIN5668247) was used to stain samples at a concentration of 3 µg/mL.



Western Blotting

Image 2. Western Blot using anti-CD4 antibody CE9.1 (Clenoliximab). Human thyroid tumour samples were resolved on a 15 % SDS PAGE gel and blots probed with the human IgG4-chimeric version of CE9.1 (ABIN5668247) at 1.5 µg/mL before detection using an anti-human IgG4 secondary antibody. Protein was detected by chemiluminescence. The expected unmodified running size for CD4 is 51 kDa (arrowhead). Here some non-specific bands can also be seen. ABIN5668247 successfully detected CD4 in human thyroid tissue samples.